Wire · opportunities
Roche's divarasib cuts death risk by 44% versus approved KRAS inhibitors in Phase III lung ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Genentech's divarasib significantly reduces death risk by 44% compared to approved KRAS G12C inhibitors sotorasib and adagrasib in a Phase III trial for previously treated KRAS G12C-mutated non-small cell lung cancer. This oral inhibitor also improves progression-free survival and has fewer treatment-related adverse events.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new benchmark for KRAS G12C therapies with divarasib showing better survival and tolerance. Start validating your pipeline against this standard or consider tackling emerging niches unmet by first-gen inhibitors.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics